Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
Pfizer’s and Moderna’s respective Omicron-adapted bivalent mRNA vaccines for COVID-19 will come up as a topic at an upcoming meeting of a Japanese health ministry panel on September 12. Their vaccines are based on the ancestral strain of the novel…
To read the full story
Related Article
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
REGULATORY
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…